Difference of Clinical and Radiological Characteristics According to Radioiodine Avidity in Pulmonary Metastases of Differentiated Thyroid Cancer

Nuclear Medicine and Molecular Imaging

Volumn 48, Issue 1, 2014, Pages 55-62

  Kim, Do Hoon ^a   Jung, Ji hoon ^a   Son, Seung Hyun ^a   Kim, Choon Young ^a   Hong, Chae Moon ^a   Jeong, Shin Young ^a   Lee, Sang Woo ^a   Lee, Jaetae ^a   Ahn, Byeong Cheol ^a  

^a Kyungpook National University School of Medicine   (South Korea)

Author keywords

Differentiated thyroid cancer; I 131 treatment; Pulmonary metastasis; Radioiodine avidity

Indexed keywords

FLUORODEOXYGLUCOSE F 18; IODINE 131; LEVOTHYROXINE; THYROGLOBULIN; THYROTROPIN;

ADOLESCENT; ADULT; AGED; ARTICLE; BONE METASTASIS; CHILD; COMPUTER ASSISTED TOMOGRAPHY; DIFFERENTIATED THYROID CANCER; DRUG MEGADOSE; DRUG WITHDRAWAL; FEMALE; FOLLOW UP; HISTOLOGY; HUMAN; HUMAN TISSUE; LIVER METASTASIS; LUNG LESION; LUNG METASTASIS; LUNG NODULE; MAJOR CLINICAL STUDY; MALE; PAPILLARY CARCINOMA; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; RADIOIMMUNOASSAY;

EID: 84896726733     PISSN: 18693474     EISSN: 18693482     Source Type: Journal    
DOI: 10.1007/s13139-013-0239-z     Document Type: Article

References (22)

1. Siegel R, Naishadham D, Jemal A. Cancer statistics, 2012. CA Cancer J Clin. 2012;62: 10-29.
2. Chen AY, Jemal A, Ward EM. Increasing incidence of differentiated thyroid cancer in the United States, 1988-2005. Cancer. 2009;115: 3801-7.
3. Sherman SI. Thyroid carcinoma. Lancet. 2003;361: 501-11.
4. O'Neill CJ, Oucharek J, Learoyd D, Sidhu SB. Standard and emerging therapies for metastatic differentiated thyroid cancer. Oncologist. 2010;15: 146-56.
5. Ruegemer JJ, Hay ID, Bergstralh EJ, Ryan JJ, Offord KP, Gorman CA. Distant metastases in differentiated thyroid carcinoma: a multivariate analysis of prognostic variables. J Clin Endocrinol Metab. 1988;67: 501-8.
6. Casara D, Rubello D, Saladini G, Masarotto G, Favero A, Girelli ME, et al. Different features of pulmonary metastases in differentiated thyroid cancer: natural history and multivariate statistical analysis of prognostic variables. J Nucl Med. 1993;34: 1626-31.
7. Kucuk ON, Gultekin SS, Aras G, Ibis E. Radioiodine whole-body scans, thyroglobulin levels, 99mTc-MIBI scans and computed tomography: results in patients with lung metastases from differentiated thyroid cancer. Nucl Med Commun. 2006;27: 261-6.
8. Ilgan S, Karacalioglu AO, Pabuscu Y, Atac GK, Arslan N, Ozturk E, et al. Iodine-131 treatment and high-resolution CT: results in patients with lung metastases from differentiated thyroid carcinoma. Eur J Nucl Med Mol Imaging. 2004;31: 825-30.
9. Ik Dong Y, Sung Hoon K, Ye Young S, Jin Kyoung O, Joo Hyun O, Soo Kyo C. The Success Rate of Initial I-131 Ablation in Differentiated Thyroid Cancer: Comparison Between Less strict and Very Strict Low Iodine Diets. Nucl Med Mol Imaging. 2012;46: 34-40.
10. Ronga G, Filesi M, Montesano T, Di Nicola AD, Pace C, Travascio L, et al. Lung metastases from differentiated thyroid carcinoma. A 40 years' experience. Q J Nucl Med Mol Imaging. 2004;48: 12-9.
11. Lorenzen J, Beese M, Mester J, Brumma K, Beyer W, Clausen M. Chest X ray: routine indication in the follow-up of differentiated thyroid cancer? Nuklearmedizin. 1998;37: 208-12.
12. Piekarski JD, Schlumberger M, Leclere J, Couanet D, Masselot J, Parmentier C. Chest computed tomography (CT) in patients with micronodular lung metastases of differentiated thyroid carcinoma. Int J Radiat Oncol Biol Phys. 1985;11: 1023-7.
13. Grunwald F, Schomburg A, Bender H, Klemm E, Menzel C, Bultmann T, et al. Fluorine-18 fluorodeoxyglucose positron emission tomography in the follow-up of differentiated thyroid cancer. Eur J Nucl Med. 1996;23: 312-9.
14. Dietlein M, Scheidhauer K, Voth E, Theissen P, Schicha H. Fluorine-18 fluorodeoxyglucose positron emission tomography and iodine-131 whole-body scintigraphy in the follow-up of differentiated thyroid cancer. Eur J Nucl Med. 1997;24: 1342-8.
15. Shiga T, Tsukamoto E, Nakada K, Morita K, Kato T, Mabuchi M, et al. Comparison of (18)F-FDG, (131)I-Na, and (201)Tl in diagnosis of recurrent or metastatic thyroid carcinoma. J Nucl Med. 2001;42: 414-9.
16. Hong CM, Ahn BC, Jeong SY, Lee SW, Lee J. Distant metastatic lesions in patients with differentiated thyroid carcinoma. Clinical implications of radioiodine and FDG uptake. Nuklearmedizin. 2013;52: 121-9.
17. Filesi M, Signore A, Ventroni G, Melacrinis FF, Ronga G. Role of initial iodine-131 whole-body scan and serum thyroglobulin in differentiated thyroid carcinoma metastases. J Nucl Med. 1998;39: 1542-6.
18. Schlumberger M, Challeton C, De Vathaire F, Travagli JP, Gardet P, Lumbroso JD, et al. Radioactive iodine treatment and external radiotherapy for lung and bone metastases from thyroid carcinoma. J Nucl Med. 1996;37: 598-605.
19. Hindie E, Melliere D, Lange F, Hallaj I, de Labriolle-Vaylet C, Jeanguillaume C, et al. Functioning pulmonary metastases of thyroid cancer: does radioiodine influence the prognosis? Eur J Nucl Med Mol Imaging. 2003;30: 974-81.
20. Pacini F, Cetani F, Miccoli P, Mancusi F, Ceccarelli C, Lippi F, et al. Outcome of 309 patients with metastatic differentiated thyroid carcinoma treated with radioiodine. World J Surg. 1994;18: 600-4.
21. Schlumberger M, Arcangioli O, Piekarski JD, Tubiana M, Parmentier C. Detection and treatment of lung metastases of differentiated thyroid carcinoma in patients with normal chest X-rays. J Nucl Med. 1988;29: 1790-4.
22. Kalender E, Zeki Celen Y, Elboga U, Deniz Demir H, Yilmaz M. Lung metastases in patients with differentiated thyroid carcinoma and evaluation of response to radioiodine therapy. Rev Esp Med Nucl Imagen Mol. 2012;31: 328-31.